Preclinical models of myocardial infarction: from mechanism to translation
Approximately 7 million people are affected by acute myocardial infarction (MI) each year, and despite significant therapeutic and diagnostic advancements, MI remains a leading cause of mortality worldwide. Preclinical animal models have significantly advanced our understanding of MI and have enable...
Gespeichert in:
| Veröffentlicht in: | British journal of pharmacology 2022-03, Vol.179 (5), p.770-791 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 791 |
|---|---|
| container_issue | 5 |
| container_start_page | 770 |
| container_title | British journal of pharmacology |
| container_volume | 179 |
| creator | Martin, Tamara P. MacDonald, Eilidh A. Elbassioni, Ali Ali Mohamed O'Toole, Dylan Zaeri, Ali Abdullah I. Nicklin, Stuart A. Gray, Gillian A. Loughrey, Christopher M. |
| description | Approximately 7 million people are affected by acute myocardial infarction (MI) each year, and despite significant therapeutic and diagnostic advancements, MI remains a leading cause of mortality worldwide. Preclinical animal models have significantly advanced our understanding of MI and have enabled the development of therapeutic strategies to combat this debilitating disease. Notably, some drugs currently used to treat MI and heart failure (HF) in patients had initially been studied in preclinical animal models. Despite this, preclinical models are limited in their ability to fully reproduce the complexity of MI in humans. The preclinical model must be carefully selected to maximise the translational potential of experimental findings. This review describes current experimental models of MI and considers how they have been used to understand drug mechanisms of action and support translational medicine development.
LINKED ARTICLES
This article is part of a themed issue on Preclinical Models for Cardiovascular disease research (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.5/issuetoc |
| doi_str_mv | 10.1111/bph.15595 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2541788553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2541788553</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4285-7ae19864c27c2031a5fdaf6ea0d597f092e0921d36014fc6a08cbb07c9d4c0543</originalsourceid><addsrcrecordid>eNp10E9LwzAYBvAgipvTg19ACl700C1pmib1psO_DNxBzyFNE5aRNjNpkX17Mzs9CAZCIO-Ph5cHgHMEpyieWbVZTREhJTkAY5TTIiWYoUMwhhDSFCHGRuAkhDWEcUjJMRjhHGFUQjwGL0uvpDWtkcImjauVDYnTSbN1UvjaxE_TauFlZ1x7k2jvmqRRciVaE5qkc0nnRRus2I1PwZEWNqiz_TsB7w_3b_OndPH6-Dy_XaQyzxhJqVCoZEUuMyoziJEguha6UALWpKQalpmKF9W4iOtqWQjIZFVBKss6l5DkeAKuhtyNdx-9Ch1vTJDKWtEq1weekRxRxgjBkV7-oWvX-zZux7MioyhSUkR1PSjpXQheab7xphF-yxHku4J5LJh_FxztxT6xrxpV_8qfRiOYDeDTWLX9P4nfLZ-GyC9ds4O9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627125456</pqid></control><display><type>article</type><title>Preclinical models of myocardial infarction: from mechanism to translation</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>Martin, Tamara P. ; MacDonald, Eilidh A. ; Elbassioni, Ali Ali Mohamed ; O'Toole, Dylan ; Zaeri, Ali Abdullah I. ; Nicklin, Stuart A. ; Gray, Gillian A. ; Loughrey, Christopher M.</creator><creatorcontrib>Martin, Tamara P. ; MacDonald, Eilidh A. ; Elbassioni, Ali Ali Mohamed ; O'Toole, Dylan ; Zaeri, Ali Abdullah I. ; Nicklin, Stuart A. ; Gray, Gillian A. ; Loughrey, Christopher M.</creatorcontrib><description>Approximately 7 million people are affected by acute myocardial infarction (MI) each year, and despite significant therapeutic and diagnostic advancements, MI remains a leading cause of mortality worldwide. Preclinical animal models have significantly advanced our understanding of MI and have enabled the development of therapeutic strategies to combat this debilitating disease. Notably, some drugs currently used to treat MI and heart failure (HF) in patients had initially been studied in preclinical animal models. Despite this, preclinical models are limited in their ability to fully reproduce the complexity of MI in humans. The preclinical model must be carefully selected to maximise the translational potential of experimental findings. This review describes current experimental models of MI and considers how they have been used to understand drug mechanisms of action and support translational medicine development.
LINKED ARTICLES
This article is part of a themed issue on Preclinical Models for Cardiovascular disease research (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.5/issuetoc</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.15595</identifier><identifier>PMID: 34131903</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>adverse cardiac remodelling ; Animal models ; Animals ; Cardiovascular diseases ; Congestive heart failure ; coronary artery ligation ; Drug development ; Heart attacks ; Heart Failure ; Humans ; ischaemia/reperfusion ; Myocardial infarction ; Myocardial Infarction - drug therapy ; Translation</subject><ispartof>British journal of pharmacology, 2022-03, Vol.179 (5), p.770-791</ispartof><rights>2021 The Authors. published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</rights><rights>2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4285-7ae19864c27c2031a5fdaf6ea0d597f092e0921d36014fc6a08cbb07c9d4c0543</citedby><cites>FETCH-LOGICAL-c4285-7ae19864c27c2031a5fdaf6ea0d597f092e0921d36014fc6a08cbb07c9d4c0543</cites><orcidid>0000-0003-3104-3305 ; 0000-0002-7771-754X ; 0000-0003-1297-9159 ; 0000-0002-9691-6210 ; 0000-0002-2509-2613 ; 0000-0003-2641-2460</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbph.15595$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbph.15595$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>315,782,786,1419,1435,27933,27934,45583,45584,46418,46842</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34131903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martin, Tamara P.</creatorcontrib><creatorcontrib>MacDonald, Eilidh A.</creatorcontrib><creatorcontrib>Elbassioni, Ali Ali Mohamed</creatorcontrib><creatorcontrib>O'Toole, Dylan</creatorcontrib><creatorcontrib>Zaeri, Ali Abdullah I.</creatorcontrib><creatorcontrib>Nicklin, Stuart A.</creatorcontrib><creatorcontrib>Gray, Gillian A.</creatorcontrib><creatorcontrib>Loughrey, Christopher M.</creatorcontrib><title>Preclinical models of myocardial infarction: from mechanism to translation</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>Approximately 7 million people are affected by acute myocardial infarction (MI) each year, and despite significant therapeutic and diagnostic advancements, MI remains a leading cause of mortality worldwide. Preclinical animal models have significantly advanced our understanding of MI and have enabled the development of therapeutic strategies to combat this debilitating disease. Notably, some drugs currently used to treat MI and heart failure (HF) in patients had initially been studied in preclinical animal models. Despite this, preclinical models are limited in their ability to fully reproduce the complexity of MI in humans. The preclinical model must be carefully selected to maximise the translational potential of experimental findings. This review describes current experimental models of MI and considers how they have been used to understand drug mechanisms of action and support translational medicine development.
LINKED ARTICLES
This article is part of a themed issue on Preclinical Models for Cardiovascular disease research (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.5/issuetoc</description><subject>adverse cardiac remodelling</subject><subject>Animal models</subject><subject>Animals</subject><subject>Cardiovascular diseases</subject><subject>Congestive heart failure</subject><subject>coronary artery ligation</subject><subject>Drug development</subject><subject>Heart attacks</subject><subject>Heart Failure</subject><subject>Humans</subject><subject>ischaemia/reperfusion</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Translation</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp10E9LwzAYBvAgipvTg19ACl700C1pmib1psO_DNxBzyFNE5aRNjNpkX17Mzs9CAZCIO-Ph5cHgHMEpyieWbVZTREhJTkAY5TTIiWYoUMwhhDSFCHGRuAkhDWEcUjJMRjhHGFUQjwGL0uvpDWtkcImjauVDYnTSbN1UvjaxE_TauFlZ1x7k2jvmqRRciVaE5qkc0nnRRus2I1PwZEWNqiz_TsB7w_3b_OndPH6-Dy_XaQyzxhJqVCoZEUuMyoziJEguha6UALWpKQalpmKF9W4iOtqWQjIZFVBKss6l5DkeAKuhtyNdx-9Ch1vTJDKWtEq1weekRxRxgjBkV7-oWvX-zZux7MioyhSUkR1PSjpXQheab7xphF-yxHku4J5LJh_FxztxT6xrxpV_8qfRiOYDeDTWLX9P4nfLZ-GyC9ds4O9</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Martin, Tamara P.</creator><creator>MacDonald, Eilidh A.</creator><creator>Elbassioni, Ali Ali Mohamed</creator><creator>O'Toole, Dylan</creator><creator>Zaeri, Ali Abdullah I.</creator><creator>Nicklin, Stuart A.</creator><creator>Gray, Gillian A.</creator><creator>Loughrey, Christopher M.</creator><general>Blackwell Publishing Ltd</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3104-3305</orcidid><orcidid>https://orcid.org/0000-0002-7771-754X</orcidid><orcidid>https://orcid.org/0000-0003-1297-9159</orcidid><orcidid>https://orcid.org/0000-0002-9691-6210</orcidid><orcidid>https://orcid.org/0000-0002-2509-2613</orcidid><orcidid>https://orcid.org/0000-0003-2641-2460</orcidid></search><sort><creationdate>202203</creationdate><title>Preclinical models of myocardial infarction: from mechanism to translation</title><author>Martin, Tamara P. ; MacDonald, Eilidh A. ; Elbassioni, Ali Ali Mohamed ; O'Toole, Dylan ; Zaeri, Ali Abdullah I. ; Nicklin, Stuart A. ; Gray, Gillian A. ; Loughrey, Christopher M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4285-7ae19864c27c2031a5fdaf6ea0d597f092e0921d36014fc6a08cbb07c9d4c0543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>adverse cardiac remodelling</topic><topic>Animal models</topic><topic>Animals</topic><topic>Cardiovascular diseases</topic><topic>Congestive heart failure</topic><topic>coronary artery ligation</topic><topic>Drug development</topic><topic>Heart attacks</topic><topic>Heart Failure</topic><topic>Humans</topic><topic>ischaemia/reperfusion</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Translation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martin, Tamara P.</creatorcontrib><creatorcontrib>MacDonald, Eilidh A.</creatorcontrib><creatorcontrib>Elbassioni, Ali Ali Mohamed</creatorcontrib><creatorcontrib>O'Toole, Dylan</creatorcontrib><creatorcontrib>Zaeri, Ali Abdullah I.</creatorcontrib><creatorcontrib>Nicklin, Stuart A.</creatorcontrib><creatorcontrib>Gray, Gillian A.</creatorcontrib><creatorcontrib>Loughrey, Christopher M.</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martin, Tamara P.</au><au>MacDonald, Eilidh A.</au><au>Elbassioni, Ali Ali Mohamed</au><au>O'Toole, Dylan</au><au>Zaeri, Ali Abdullah I.</au><au>Nicklin, Stuart A.</au><au>Gray, Gillian A.</au><au>Loughrey, Christopher M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preclinical models of myocardial infarction: from mechanism to translation</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2022-03</date><risdate>2022</risdate><volume>179</volume><issue>5</issue><spage>770</spage><epage>791</epage><pages>770-791</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>Approximately 7 million people are affected by acute myocardial infarction (MI) each year, and despite significant therapeutic and diagnostic advancements, MI remains a leading cause of mortality worldwide. Preclinical animal models have significantly advanced our understanding of MI and have enabled the development of therapeutic strategies to combat this debilitating disease. Notably, some drugs currently used to treat MI and heart failure (HF) in patients had initially been studied in preclinical animal models. Despite this, preclinical models are limited in their ability to fully reproduce the complexity of MI in humans. The preclinical model must be carefully selected to maximise the translational potential of experimental findings. This review describes current experimental models of MI and considers how they have been used to understand drug mechanisms of action and support translational medicine development.
LINKED ARTICLES
This article is part of a themed issue on Preclinical Models for Cardiovascular disease research (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.5/issuetoc</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>34131903</pmid><doi>10.1111/bph.15595</doi><tpages>22</tpages><orcidid>https://orcid.org/0000-0003-3104-3305</orcidid><orcidid>https://orcid.org/0000-0002-7771-754X</orcidid><orcidid>https://orcid.org/0000-0003-1297-9159</orcidid><orcidid>https://orcid.org/0000-0002-9691-6210</orcidid><orcidid>https://orcid.org/0000-0002-2509-2613</orcidid><orcidid>https://orcid.org/0000-0003-2641-2460</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1188 |
| ispartof | British journal of pharmacology, 2022-03, Vol.179 (5), p.770-791 |
| issn | 0007-1188 1476-5381 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2541788553 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection |
| subjects | adverse cardiac remodelling Animal models Animals Cardiovascular diseases Congestive heart failure coronary artery ligation Drug development Heart attacks Heart Failure Humans ischaemia/reperfusion Myocardial infarction Myocardial Infarction - drug therapy Translation |
| title | Preclinical models of myocardial infarction: from mechanism to translation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T06%3A17%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preclinical%20models%20of%20myocardial%20infarction:%20from%20mechanism%20to%20translation&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Martin,%20Tamara%20P.&rft.date=2022-03&rft.volume=179&rft.issue=5&rft.spage=770&rft.epage=791&rft.pages=770-791&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.15595&rft_dat=%3Cproquest_cross%3E2541788553%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627125456&rft_id=info:pmid/34131903&rfr_iscdi=true |